Sign in
Not yet recruitingPhase 1/2

Lemborexant for Cannabis Use Disorder

Key facts

Who runs it
University of Calgary
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
28 people, planned
Started
Nov 2026
Expected to end
Nov 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Lemborexant 10mg
  • Placebo
  • Brief Behavioural Intervention
Record updated
22 September 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Moderate to severe Cannabis Use Disorder
  • Ability to read/write in English

Who cannot take part

  • Current or recent (within the past 12 weeks) participation in a clinical trial involving medication administration
  • Known allergies or hypersensitivities to Lemborexant
  • Narcolepsy, Complex sleep behaviors, sleep apnea, restless leg syndrome, and Periodic Limb Movement Disorder
  • Moderate to severe hepatic impairment
  • Past or ongoing moderate to severe psychiatric disorders
  • Epilepsy or history of seizures
  • Use of any Orexin-Antagonist in the past 3 months
  • Currently undergoing treatment for CUD
  • Any hospitalization or emergency department visit related to cannabis use
  • Active suicidal ideation or serious attempt within the past 3 years
  • Blood pressure over 160/95mmHg at the screening session
  • Current pregnancy or nursing, trying to become pregnant, or unwilling to use acceptable method of contraception during the study

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Cannabis use disorder

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to investigate the use of Lemborexant as a treatment for moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answer are:

Read full original descriptionShow less

1. Is Lemborexant safe, feasible, and tolerable to use in the CUD population? 2. Will the use of Lemborexant for CUD help to decrease cannabis use, improve sleep, decrease cannabis withdrawal symptoms, and improve cognition?

Researchers will compare 10mg Lemborexant to placebo.

Participants will:

* Take 10mg Lemborexant (or placebo) nightly for 21 nights (treatment phase). * Wear an actigraphy watch continuously for the treatment phase. * Complete a pre-screen survey, attend an in-person screening session, 4 in-person lab visits (weekly from days 0-21), and a virtual follow-up visit 2 weeks after the treatment phase. * Complete a short daily survey for 35 days total.

The 2 groups in the trial

  • Lemborexant 10mgTreatment being tested

    Treatment: Lemborexant 10mg and Brief Behavioural Intervention

  • PlaceboPlacebo, for comparison

    Treatment: Placebo and Brief Behavioural Intervention

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lemborexant as a Potential Pharmacotherapy for the Treatment of Cannabis Use Disorder (CUD)
Criteria questions
Built from NCT07802990, who can take part
Record updated
22 September 2026